JP2021506275A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506275A5 JP2021506275A5 JP2020532815A JP2020532815A JP2021506275A5 JP 2021506275 A5 JP2021506275 A5 JP 2021506275A5 JP 2020532815 A JP2020532815 A JP 2020532815A JP 2020532815 A JP2020532815 A JP 2020532815A JP 2021506275 A5 JP2021506275 A5 JP 2021506275A5
- Authority
- JP
- Japan
- Prior art keywords
- tnfr
- nucleic acid
- chimeric
- item
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 56
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 21
- 230000011664 signaling Effects 0.000 claims description 20
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 18
- 108091008874 T cell receptors Proteins 0.000 claims description 18
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 108020001756 ligand binding domains Proteins 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 101150117815 D3R gene Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 101100222866 Vaccinia virus (strain Ankara) MVA100R gene Proteins 0.000 claims description 2
- 101100222869 Vaccinia virus (strain Western Reserve) VACWR108 gene Proteins 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- -1 RANK Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720949.5A GB201720949D0 (en) | 2017-12-15 | 2017-12-15 | Cell |
| GB1720949.5 | 2017-12-15 | ||
| PCT/GB2018/053629 WO2019116046A1 (en) | 2017-12-15 | 2018-12-14 | Cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506275A JP2021506275A (ja) | 2021-02-22 |
| JP2021506275A5 true JP2021506275A5 (enExample) | 2021-11-25 |
Family
ID=61009002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532815A Withdrawn JP2021506275A (ja) | 2017-12-15 | 2018-12-14 | 細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12304942B2 (enExample) |
| EP (2) | EP3724320B1 (enExample) |
| JP (1) | JP2021506275A (enExample) |
| CN (1) | CN111479918A (enExample) |
| AU (1) | AU2018383084A1 (enExample) |
| CA (1) | CA3086360A1 (enExample) |
| ES (1) | ES3039696T3 (enExample) |
| GB (1) | GB201720949D0 (enExample) |
| WO (1) | WO2019116046A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| EP4132962A1 (en) * | 2020-04-09 | 2023-02-15 | Autolus Limited | Molecule |
| CN115315439A (zh) * | 2020-04-09 | 2022-11-08 | 奥托路斯有限公司 | 细胞 |
| TW202220677A (zh) * | 2020-07-31 | 2022-06-01 | 日商中外製藥股份有限公司 | 含有表現嵌合受體之細胞的醫藥組成物 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| US20240076351A1 (en) * | 2021-01-15 | 2024-03-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Hybrid and truncated immune cell proteins |
| EP4504222A4 (en) * | 2022-04-07 | 2026-04-15 | Univ Texas | METHODS FOR ACTIVATING AND EXPANDING MODIFIED NATURAL KILLER CELLS AND COMBINATIONS WITH ANTIBODIES |
| JP2025522824A (ja) * | 2022-07-01 | 2025-07-17 | フェイト セラピューティクス，インコーポレイティド | 養子細胞療法におけるエフェクター細胞の耐久性及び有効性の増強 |
| CN120535659B (zh) * | 2025-07-29 | 2025-10-17 | 苏州大学 | 一种骨靶向的三聚体蛋白及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
| JP2002541845A (ja) | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| EP3230310B1 (en) * | 2014-12-08 | 2019-06-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd70 chimeric antigen receptors |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN106467906B (zh) * | 2015-08-20 | 2019-09-27 | 北京马力喏生物科技有限公司 | 构建体、转基因淋巴细胞及其制备方法和用途 |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CN115315439A (zh) | 2020-04-09 | 2022-11-08 | 奥托路斯有限公司 | 细胞 |
-
2017
- 2017-12-15 GB GBGB1720949.5A patent/GB201720949D0/en not_active Ceased
-
2018
- 2018-12-14 EP EP18822462.0A patent/EP3724320B1/en active Active
- 2018-12-14 WO PCT/GB2018/053629 patent/WO2019116046A1/en not_active Ceased
- 2018-12-14 AU AU2018383084A patent/AU2018383084A1/en not_active Abandoned
- 2018-12-14 CN CN201880080935.1A patent/CN111479918A/zh active Pending
- 2018-12-14 JP JP2020532815A patent/JP2021506275A/ja not_active Withdrawn
- 2018-12-14 EP EP25181423.2A patent/EP4628503A3/en active Pending
- 2018-12-14 CA CA3086360A patent/CA3086360A1/en active Pending
- 2018-12-14 ES ES18822462T patent/ES3039696T3/es active Active
- 2018-12-14 US US16/772,260 patent/US12304942B2/en active Active